

1/7

Fig.1 Scheme of the method for detection of thrombolytic action of drugs *in vivo* in rats (according to Gryglewski et al..)




Fig. 2. Thrombolytic response *in vivo* induced by intravenous MNA<sup>+</sup> (30 mg/kg) administration






Fig. 3. Changes in plasma levels of 6-keto-PGF<sub>1α</sub> (●) and TXB<sub>2</sub> (○) after intravenous administration of MNA<sup>+</sup> (30 mg/kg)




3/7

Fig. 4. Lack of thrombolytic response after intravenous administration of nicotinamide or nicotinic acid (30 mg/kg).



4/7

Fig. 5. Lack of thrombolytic response after intravenous administration of 2-PYR or trigonelline (30 mg/kg).



5/7

Fig. 6. Thrombolytic response induced by intravenous administration of MAP<sup>+</sup> (30 mg/kg)






Fig. 7. Changes in plasma levels of 6-keto-PGF<sub>1α</sub> (●) and TXB<sub>2</sub> (○) after intravenous administration of MAP<sup>+</sup> (30 mg/kg)



6/7

Fig. 8. Thrombolytic response induced by intravenous administration of MNAF<sup>+</sup> (30 mg/kg)



7/7

Fig. 9 Lack of effect of MNA<sup>+</sup> on collagen-induced aggregation of platelets




Fig. 10 Lack of effect of MNA<sup>+</sup> on latex-induced activation of neutrophils

